| || || |
3-5 stars based on
Neurontin belongs to the class of anticonvulsant medicines. It is an anti-epileptic medication.
Neurontin capsules 300 mg /day) 1 day
Fluid overload (i.e. > 1.5L/min) and hyperkalaemia (blood glucose > 250 mOsm).
The following patients were started on clopidogrel but later stopped because of the potential interaction with anticoagulants warfarin and heparin:
Women and men aged >70 years without risk factors.
Patient's must be stable on low doses of clopidogrel in the past.
Clopidogrel was started at an appropriate dose or reduced in approximately 10% of clopidogrel-treated patients (> or =50 mg/day of a single, dose-finding study). The number of tablets was increased or decreased at the discretion of patient/caregiver by adjusting the maintenance dose if required until stabilization of the clotting profile.
Patients should be placed on maintenance (not a second-line) medications, Neurontin oral capsule 300 mg which may include non-steroidal anti-inflammatory drugs (NSAIDs; such as aspirin (0.02-0.1-1 mg/day) and non-steroidal anti- inflammatory drugs (NSAIDs; such as ibuprofen 1-2 mg/day), ticlopidine mg/day, or metoprolol 40-80 mg/day).
If the patient is in a clinical trial, he or she should be switched from a trial agent to maintenance at the end of medication schedule.
Patients taking warfarin and heparin should be switched from warfarin to clopidogrel in the treatment decision-making process.
Clopidogrel is started in clinical trials patients the first week of open label duration (see Drug Interactions), or in the first week of open-label therapy in patients not receiving warfarin or heparin. Patients are switched from clopidogrel to a maintenance therapy at the end of trial (see Drug Interactions).
Patients aged â‰¥60 years not receiving clopidogrel may be switched from warfarin or heparin to clopidogrel before the initiation of trial regimen, to minimize the risk for concomitant thromboembolic events and reduce blood loss resulting from the discontinuation of drug therapy [see Interactions].
Patients receiving clopidogrel should be switched from warfarin to clopidogrel if at least 1 patient in the trial was already on warfarin or heparin before switching to clopidogrel.
Patients requiring a first-line anticoagulant should be switched to clopidogrel, especially in patients who experience an adverse effect with clopidogrel. These patients should be switched to a lower effective dosage (either serum concentrations or higher platelet doses) before initiating a higher dose (see Drug Interactions).
If the potential interaction between clopidogrel and other anticoagulants has arisen from a clinical trial, it is necessary to switch patients from that therapy at the